Zobrazeno 1 - 5
of 5
pro vyhledávání: '"Gerard Barron"'
Autor:
Kaushik Patra, Soraya Madani, Armando Flor, Gabriela Klodowska-Duda, Mark Agius, Jing Li, Maciej Maciejowski, Eliezer Katz, Andrzej Potemkowski, Gerard Barron, Jacob Wesley
Publikováno v:
Multiple Sclerosis (Houndmills, Basingstoke, England)
Background: B cells may be involved in the pathophysiology of multiple sclerosis (MS). Inebilizumab (formerly MEDI-551) binds to and depletes CD19+ B cells. Objectives: To assess safety, tolerability, pharmacokinetics, pharmacodynamics and immunogeni
Autor:
Dewei She, Sean J. Pittock, Jeffrey Bennett, Soraya Madani, Jorn Drappa, Bruce A.C. Cree, Ho Jin Kim, Brian G. Weinshenker, Fred D. Lublin, Friedemann Paul, Romain Marignier, John N. Ratchford, Dean M. Wingerchuk, Eliezer Katz, Orhan Aktas, Gary Cutter, N-MOmentum study investigators, Daniel Cimbora, Kazuo Fujihara, Gerard Barron, Hans-Peter Hartung, Ari J. Green
Publikováno v:
Lancet (London, England). 394(10206)
No approved therapies exist for neuromyelitis optica spectrum disorder (NMOSD), a rare, relapsing, autoimmune, inflammatory disease of the CNS that causes blindness and paralysis. We aimed to assess the efficacy and safety of inebilizumab, an anti-CD
Autor:
Jeffrey A. Cohen, Brian G. Weinshenker, Hans-Peter Hartung, Friedemann Paul, Ho Jin Kim, Jeffrey Bennett, Mark Sheehan, Soraya Madani, John N. Ratchford, Sean J. Pittock, Eliezer Katz, Kazuo Fujihara, Gary Cutter, Orhan Aktas, Gerard Barron, Dean M. Wingerchuk, Bruce A.C. Cree, Armando Flor, Kaushik Patra
Publikováno v:
Multiple Sclerosis (Houndmills, Basingstoke, England)
Background: To date, no treatment for neuromyelitis optica (NMO) has been granted regulatory approval, and no controlled clinical studies have been reported. Objective: To design a placebo-controlled study in NMO that appropriately balances patient s
Autor:
Terrence F. Blaschke, Aysha Keisler, Janine Beekman, Lawrence J. Cook, Jacinta M. Behne, Omar Pedraza, Masayuki Haramura, Terry J. Smith, Gerard Barron, Athos Gianella-Borradori, Michael R. Yeaman, John N. Ratchford, Eliezer Katz
Publikováno v:
Neurology® Neuroimmunology & Neuroinflammation
ObjectiveTo gain insights into NMOSD disease impact, which may negatively affect QoL of patients, their families, and social network.MethodsThe current study used validated instruments to assess physical, emotional, and socioeconomic burden of NMOSD
Autor:
Jeffery L. Bennett, Angela T. Melia, Brian G. Weinshenker, Susan VanMeter, Jérôme De Seze, Terry J. Smith, Peter Chin, Kazuo Fujihara, Armando Flor, Pablo Villoslada, Gerard Barron, Jacinta M. Behne, Omar Khan, William Holt, Michael J. Levy, Warren W. Wasiewski, Jacqueline Palace, Benjamin Greenberg, Marc K. Walton, Dean M. Wingerchuk, Michael R. Yeaman, Katja Van Herle, Volker Knappertz, Sayumi Higashi, Bruce A.C. Cree, Maria Pia Sormani
Publikováno v:
Neurology
Current management of neuromyelitis optica (NMO) is noncurative and only partially effective. Immunosuppressive or immunomodulatory agents are the mainstays of maintenance treatment. Safer, better-tolerated, and proven effective treatments are needed
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::dc51c1d23930bd091c97f1837aacef0c